COPD Connect
  • Saved

2mo
case study

Patient Background:

Mr. H is a 66-year-old male retired factory worker with a 45-pack-year smoking history who currently smokes 5 cigarettes daily. He has a 5-year history of chronic obstructive pulmonary disease (COPD) and reports worsening exertional dyspnea (mMRC grade 2), chronic productive morning cough, and one moderate COPD exacerbation during the past year requiring oral corticosteroids.

He has been receiving inhaled long-acting muscarinic antagonist (LAMA) monotherapy for 2 years with partial symptom control. Comorbidities include hypertension and benign prostatic hypertrophy managed with tamsulosin. He has no history of asthma or eosinophilia.

Assessment & Diagnosis:

Spirometry demonstrates an FEV1/FVC ratio of 0.58 and FEV1 of 56% predicted, consistent with GOLD Stage 2, Group B COPD. COPD Assessment Test (CAT) score is 18, indicating…read more

high symptom burden. Six-minute walk test distance is 310 meters. CT imaging demonstrates emphysema-predominant disease.

Given persistent dyspnea despite LAMA monotherapy and absence of eosinophilia or asthma features, the care team escalates to once-daily dual bronchodilator therapy using a fixed-dose LAMA/LABA combination administered via a soft mist inhaler. Smoking cessation counseling was reinforced.

  1. Please provide a minimum of a 3 sentence response.
  2. 1.Which COPD phenotype features support escalation from LAMA monotherapy to fixed-dose LAMA/LABA therapy?
  3. 2.What inhaler technique and adherence barriers should be assessed when initiating soft mist inhaler therapy?
  4. 3.How should symptom burden and functional response be monitored after escalation to dual bronchodilator therapy?

Show Less

  • 2mo
    This patient with Chronic Obstructive Pulmonary Disease shows clear features supporting escalation from LAMA monotherapy to fixed-dose LAMA/LABA therapy, including persistent dyspnea (mMRC ≥2), elevated symptom burden (CAT 18), and Show More
  • 2mo
    1: patients without a steroid responding component who are symptomatic. 2: usually have the nurse do training initially and at follow up visits 3: exacerbations and continuing symptoms should prompt Show More
  • Saved

2mo
The multifaceted role of FAM13A in pulmonary diseases. - PubMed

The multifaceted role of FAM13A in pulmonary diseases. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42266412

Discover FAM13A's roles in lung diseases: exacerbating COPD, alleviating fibrosis in PF, influenced by genetic and environmental factors.


FAM13A modulates Rho and Wnt/β-catenin pathways, worsening COPD but reducing fibrosis in PF. Isoform diversity and environmental factors complicate its study.

  • Saved

2mo
Peak inspiratory flow in Austrian patients with Asthma and/or COPD using dry powder inhalers- A Cross-Sectional, Observational Real-World Study - PubMed

Peak inspiratory flow in Austrian patients with Asthma and/or COPD using dry powder inhalers- A Cross-Sectional, Observational Real-World Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42251916/

A considerable proportion of asthma and COPD patients does not achieve the optimal PIF for effective drug delivery to the lungs, some even fail to generate the minimal PIF which...

Real-world assessment found nearly one-quarter of COPD patients using dry powder inhalers failed to achieve optimal inspiratory flow, highlighting the importance of inhaler selection, training, and peak flow evaluation.

  • Saved

2mo
Can dual bronchodilation influence cardiac function in patients with COPD?

COPD is increasingly recognized as a systemic disease, with cardiovascular dysfunction and autonomic imbalance contributing to patient burden beyond airflow limitation. This raises an important question: can improving lung mechanics also affect cardiac health?

Emerging evidence from a recent study suggests that dual bronchodilator therapy may improve not only lung function, but also selected cardiac parameters in patients with moderate-to-severe COPD. Over 12 weeks, treatment was associated with significant gains in FEV1 and reductions in measures of air trapping. Improvements were also observed in cardiac index and late heart-to-mediastinum ratio, a marker associated with autonomic function. These findings suggest a potential link between relieving hyperinflation and reducing cardiopulmonary strain.

The study also reported that biomarkers such as high-sensitivity C-reactive protein were associated with worse pulmonary function at baseline, highlighting the role of systemic inflammation in COPD and its broader clinical impact. Taken together, these findings reinforce the need to view COPD through a multisystem lens, where optimizing bronchodilation may have implications beyond symptom control alone.

How often do you consider cardiac consequences when optimizing therapy in COPD? Could improvements in lung hyperinflation meaningfully alter cardiovascular risk in your patients?

  • 2mo
    It is essential to look at the patient holistically and it is logical that improving pulmonary function improves cardiac function. The emphasis on preventing exacerbations prevents unnecessary cardiopulmonary strain.
  • 2mo
    This is very important information to bring to this community’s attention. I will keep in mind

Show More Comments

  • Saved

2mo
Application of machine learning models for predicting risk factors of acute exacerbations in chronic obstructive pulmonary disease - PubMed

Application of machine learning models for predicting risk factors of acute exacerbations in chronic obstructive pulmonary disease - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42221119/

The XGBoost model developed in this study demonstrates robust performance in predicting AECOPD risk using routinely collected clinical and laboratory data. The integration of SHAP analysis enhances model transparency, supporting...

Machine learning analysis identified key predictors of acute COPD exacerbations, with XGBoost demonstrating strong predictive performance and highlighting creatinine, neutrophils, D-dimer, BNP, hypertension, and leukocyte count.